Venture funding displays a mixed trend as overall investments decline while larger megadeals increase. In 2024, U.S.-based startups reported nearly 240 funding rounds of $100 million or more, surpassing last year's 210 rounds. Biotech and healthcare sectors lead with 87 megadeals, including significant amounts like over $1 billion for Xaira Therapeutics and around $720 million for Radiology Partners. The artificial intelligence sector also sees major investments, with OpenAI securing $6.6 billion and xAI raising $6 billion. Additionally, 11 U.S. startups have raised over $1 billion this year, up from 10 last year. The year is projected to approach 300 megadeals, reflecting heightened investor interest in companies with high growth potential, despite overall venture funding challenges. Data tracking focuses on U.S.-based startups and their funding by industry, illustrating current investment trends.

Learn more on this news visit us at:

https://theweb3.news/news-bites/why-are-megadeals-surging-despite-venture-slowdown/

Hosted on Acast. See acast.com/privacy for more information.